VenatoRx Pharmaceuticals Receives FDA’s QIDP and Fast Track Designations for Development of its Lead Antibiotic Program

By

VenatoRx Pharmaceuticals Receives FDA’s QIDP and Fast Track Designations for Development of its Lead Antibiotic Program 

See more here

Comments are closed.